Back to Journals » Biologics: Targets and Therapy » Volume 4
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
12,772 | Dovepress* | 12,772+ | 2,690 | 15,462 | |
Totals | 12,772 | 2,690 | 15,462 | ||
*Since 30 April 2010 +Since July 2016 |
View citations on Google Scholar